Strasbourg, France, September 19th 2023 – Polyplus part of Satorius, a leading upstream solutions provider for advanced biologic and cell and gene therapy production from research to commercial grade, has announced the introduction of pPLUS® AAV-Helper for enhanced AAV production efficiency and reduced cost per dose. The novel pHelper plasmid integrates new helper elements in a unique sequence that also improve viral vector quality.
pPLUS® AAV-Helper plasmid was developed with e-Zyvec® technology and optimized for transfection with FectoVIR®-AAV transfection reagent. The new addition expands the product portfolio beyond transfection reagents with another critical raw material for the AAV production process. All products are available at quality levels required by the industry to enable seamless scalability.
“Following the acquisition of e-Zyvec, a company specialized in plasmid engineering, we are happy to launch this new, enabling AAV phelper plasmid. Production will be supported by our owned affiliate, Xpress Biologics, specialized in plasmid DNA manufacturing, with the capacity to produce R&D, HQ and GMP grade pDNA for gene therapy manufacturing, ensuring a secure our supply chain,” Mario Philips, CEO explained. “We will continue to execute on our strategy of being a first-choice upstream process supplier with best-in-class raw materials that help optimize process economics with thoughtful additions to the product and services portfolio.”
The pPLUS® AAV-Helper plasmid is a new critical component in the AAV manufacturing process that enable customers to improve upstream process efficiencies and reduce cost per dose of gene-replacement therapies. More products (such as pRep/Cap plasmids) as well as other components for AAV production upstream process optimization are in development. Learn more and follow the Polyplus journey to power your science here: https://www.polyplus-sartorius.com/
About Polyplus
Polyplus, part of Sartorius, is a leading upstream solutions provider for advanced biologic and cell and gene therapy production from research to commercial scale. The legacy nucleic acid delivery portfolio features process-centric transfection reagents, kits, and support services including bioproduction industry standard, PEIpro® and FectoVIR®-AAV. In 2020, the company began focusing on upstream bioprocess economic optimization with the addition of custom plasmid vector design, GMP transfection reagent and plasmid manufacturing with an internalized supply chain designed to meet strict scientific and regulatory standards. Headquartered in Europe, the Polyplus team continues to grow globally with operations in the United States and Asia.
Media Contact Information:
Alengo Nyamay’antu, PhD
Marketing & Communication team leader
an@polyplus-transfection.com
Direct: +33 3 88 67 59 38